First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer

被引：0
|
作者：
Ohta, Katsuya [1 ,2 ]
Ikenaga, Masakazu [2 ]
Uemura, Mamoru [3 ]
Sakata, Kazuya [2 ,4 ]
Nishimura, Junichi [5 ]
Hata, Taishi [5 ]
Matsuda, Chu [5 ]
Mizushima, Tsunekazu [5 ]
Doki, Yuichiro [5 ]
Mori, Masaki [5 ]
机构：
[1] Colorectal Canc Treatment Grp MCSGO, Multictr Clin Study Grp Osaka, Osaka, Japan
[2] Osaka Univ, Dept Surg Gastroenterol, Suita, Osaka, Japan
[3] Higashiosaka City Gen Hosp, Dept Surg, Higashiosaka, Osaka, Japan
[4] Natl Hosp Org, Osaka Natl Hosp, Dept Surg, Osaka, Japan
[5] Osaka Univ, Dept Surg Gastroenterol, Suita, Osaka, Japan
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2016年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1549
引用
收藏
页码：216 / 216
页数：1
相关论文
共 50 条
  • [1] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Uemura, Mamoru
    Kim, Ho Min
    Hata, Tsuyoshi
    Sakata, Kazuya
    Okuyama, Masaki
    Takemoto, Hiroyoshi
    Fujii, Hitoshi
    Fukuzaki, Takayuki
    Morita, Tetsushi
    Hata, Taishi
    Takemasa, Ichiro
    Satoh, Taroh
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Maski
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (02) : 375 - 379
  • [2] Cetuximab or BevacizumabWith First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer No Difference, but Not the Same
    Lieu, Christopher H.
    Messersmith, Wells A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (23): : 2376 - 2378
  • [3] Continued cetuximab in second-line treatment for patients with unresectable metastatic wild-type KRAS, NRAS, and BRAF colorectal cancer after disease progression during first-line cetuximab-based therapy
    Liu, Ying
    Wang, Feng
    Ma, Ning
    Xu, Shuning
    Qiao, Lei
    Li, Ke
    Kuang, Gaizhen
    Li, Danyang
    Liu, Yangyang
    Xiong, Yanyan
    Sun, Mingming
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [4] QUALITY OF LIFE ANALYSIS IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE FOLFIRI PLUS CETUXIMAB
    Lang, I.
    Koehne, C.
    Folprecht, G.
    Rougier, P.
    Curran, D.
    Hitre, E.
    Sartorius, U.
    Griebsch, I.
    Van Cutsem, E.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 191 - 192
  • [5] Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
    Patel, Shiven B.
    Gill, David
    Garrido-Laguna, Ignacio
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 75 - 86
  • [6] Therapeutic effect of biweekly cetuximab combined with first-line chemotherapy on KRAS/RAS wild-type advanced colorectal cancer
    Li, Jing
    Li, Jianjiong
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (10): : 12348 - 12355
  • [7] Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer
    Ewara, E. M.
    Zaric, G. S.
    Welch, S.
    Sarma, S.
    [J]. CURRENT ONCOLOGY, 2014, 21 (04) : E541 - E550
  • [8] Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
    Venook, Alan P.
    Niedzwiecki, Donna
    Lenz, Heinz-Josef
    Innocenti, Federico
    Fruth, Briant
    Meyerhardt, Jeffrey A.
    Schrag, Deborah
    Greene, Claire
    O'Neil, Bert H.
    Atkins, James Norman
    Berry, Scott
    Polite, Blase N.
    O'Reilly, Eileen M.
    Goldberg, Richard M.
    Hochster, Howard S.
    Schilsky, Richard L.
    Bertagnolli, Monica M.
    El-Khoueiry, Anthony B.
    Watson, Peter
    Benson, Al B., III
    Mulkerin, Daniel L.
    Mayer, Robert J.
    Blanke, Charles
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (23): : 2392 - 2401
  • [9] USE OF CETUXIMAB-BASED THERAPY AS SECOND-LINE TREATMENT IN KRAS WILD-TYPE METASTATIC COLORECTAL CARCINOMAS (mCRC)
    Gurusamy, P.
    Hashim, M. A.
    Nguyen, H.
    Iddawela, M.
    Wong, Z. W.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 55 - 55
  • [10] Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin
    Lang, Istvan
    Koehne, Claus-Henning
    Folprecht, Gunnar
    Rougier, Philippe
    Curran, Desmond
    Hitre, Erika
    Sartorius, Ute
    Griebsch, Ingolf
    Van Cutsem, Eric
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (02) : 439 - 448
12345